saxagliptin sold brand name onglyza oral hypoglycemic antidiabetic drug dipeptidyl inhibitor early development solely bristolmyers squibb astrazeneca joined bristolmyers squibb codevelop final compound collaborate marketing drug april us fda added warning increased risk heart based data article concluded inhibition saxagliptin increase decrease rate ischemic events though rate hospitalization heart failure increased although saxagliptin improves glycemic control approaches necessary reduce cardiovascular risk patients saxagliptin used monotherapy combination drugs treatment type diabetes appear decrease risk heart attacks one study showed risk hospitalization heart failure compared placebocontrolled group like inhibitors relatively modest lowering ability associated relatively low risk hypoglycemia cause weight saxagliptin improved mean levels relative placebo trial people type combination therapy saxagliptin metformin effective saxagliptin metformin relative benefits increasing dose sulfonylurea adding saxagliptin assessed study patients combination treatments shown significantly greater impact fasting blood glucose increasing tested glibenclamide dose taking sulphonylureas increased risk low blood adverse reactions seen higher saxagliptin vs placebo table adverse reactions regardless investigator assessment causality placebocontrolled trials reported patients treated onglyza saxagliptin tablets mg commonly patients treated february bristolmyersastra zeneca distributed additional safety information saxagliptin use south africa package insert edited south africa contraindications include history sensitivity saxagliptin another inhibitor well pancreatitis spontaneously reported adverse events south africa included anaphylaxis angioedema acute pancreatitismedical citation needed cardiovascular outcomes trial saxagliptin treatment let small increase risk hospitalized heart saxagliptin may cause joint pain severe saxagliptin may increase risk heart monotherapy combination therapy agents generally well tolerated clinical association dppiv inhibitor class pancreatic problems proposed mainly based case reports associated dppiv inhibitor sitagliptin several incretin mimetics including exenatide study inhibitor sitagliptin reported found worrisome changes pancreases rats could lead pancreatic second paper authors reported increase precancerous lesions pancreases organ donors taken response reports united states fda european medicines agency undertook independent reviews clinical preclinical data related possible association dppiv inhibitors pancreatic cancer joint letter new england journal medicines agencies stated agencies agree assertions concerning causal association incretinbased drugs pancreatitis pancreatic cancer expressed recently scientific literature media inconsistent current data fda ema reached final conclusion time regarding causal relationship although totality data reviewed provides reassurance pancreatitis continue considered risk associated drugs data available agencies continue investigate safety lawsuits filed plaintiffs developed pancreatic cancer claim dppiv inhibitors incretins causative role development synthesis saxagliptin bristolmyers squibb amide coupling methanoprolineamide edc former commercially available whereas latter available nboc analog prolineamide moiety subsequently dehydrated trifluoroacetic anhydride give cyanide trifluoracetate ester hydrolyzed removal boc protecting group followed neutralization gives desired product saxagliptin part class diabetes medications called dipeptidyl inhibitors enzyme breaks incretin hormones inhibitor saxagliptin slows breakdown incretin hormones increasing level hormones body increase incretin hormones responsible beneficial actions saxagliptin including increasing insulin production response meals decreasing rate gluconeogenesis dipeptidyl role blood glucose regulation thought degradation degradation incretin hormones active response higher blood sugar levels less active response low blood sugar risk dangerously low blood sugar hypoglycemia low saxagliptin monotherapy new drug application saxagliptin treatment type diabetes submitted fda june based drug development program randomized trials phase doseranging mgd study phase controlled trials additional controlled followup months doubleblinded throughout one mechanismofaction trial followup fda approved saxagliptin brand name onglyza july saxagliptin licensed use throughout european union european medicines agency december bristolmyers squibb announced december otsuka pharmaceutical co granted exclusive rights develop commercialize compound japan licensing agreement otsuka responsible development costs bristolmyers squibb retains rights copromote saxagliptin otsuka january announced bristolmyers squibb astrazeneca would work together complete development drug subsequent httpsenwikipediaorgwikisaxagliptin